Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Stefan D. Gross, R. Xu, M. Boys, K. Condroski, L. DeMeese, W.E. DeWolf, B. Fell, J. Fischer, S. Gloor, M. J. Humphries, G. Miknis, K. Regal, M.Rodriguez, N. Raddatz, K. Shotts, G. Topalov, E. Wallace, J. Zuzack, J. A. Josey, J. Winkler, Kevin Koch | ||||||||||||
Title | Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/70/8_Supplement/4484.short | ||||||||||||
Abstract Text | for oncology. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AR-mTOR-26 | AR-mTOR-26 | 1 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AR-mTOR-26 | AR mTOR 26 | mTOR Inhibitor 51 | AR-mTOR-26 is a selective inhibitor of mTOR, which leads to decreased signaling through mTORC1 and mTORC2, and may lead to decreased tumor growth (Cancer Res April 15, 2010 70; 4484, PMID: 20024839). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | prostate cancer | predicted - sensitive | AR-mTOR-26 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in prostate cancer xenograft models with PTEN loss (Cancer Res 2010;70(8 Suppl):Abstract nr 4484). | detail... |